

# Ana Brandusa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6298302/publications.pdf>

Version: 2024-02-01

7  
papers

238  
citations

1684129

5  
h-index

1872665

6  
g-index

7  
all docs

7  
docs citations

7  
times ranked

284  
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to “Lack of efficacy of dupilumab in the treatment of keloid disorder”™ by MH Tirgan and J Uitto. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	0
2	Transcriptomic Analysis of the Major Orphan Ichthyosis Subtypes Reveals Shared Immune and Barrier Signatures. Journal of Investigative Dermatology, 2022, 142, 2363-2374.e18.	0.7	11
3	Kallikrein 7 Promotes Atopic Dermatitis-Associated Itch Independently of Skin Inflammation. Journal of Investigative Dermatology, 2020, 140, 1244-1252.e4.	0.7	36
4	Keloid lesions show increased IL-4/IL-13 signaling and respond to Th2-targeting dupilumab therapy. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e161-e164.	2.4	50
5	Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing. British Journal of Dermatology, 2020, 183, 1083-1093.	1.5	40
6	544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1). Journal of Investigative Dermatology, 2019, 139, S94.	0.7	5
7	The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. British Journal of Dermatology, 2019, 181, 733-742.	1.5	96